Given that glioma patients are usually immunosuppressed, and the infiltration and polarization of macrophage and neutrophils are the major cause for glioma resistance to chemotherapy and radiotherapy (21, 77), it was reasonable to predict that MD2 may be involved in the process of drug resistance by regulating immune response in glioma. This evidence concerns the gene LY96 and central nervous system cancer.